Immune to Cancer: The CRI Blog
-
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints
The latest advances in using new checkpoint drugs to target LAG-3, Nrp1, IL-35R, CD36, and mitochondrial metabolism.
-
CICON16: Cancer Antigens and the Development of Personalized Immunotherapy Approaches
Antigens are the key to effective vaccines and the immune system’s ability to target cancer cells.
-
CICON16: Translating Science Into Survival
This Sunday, we are proud to welcome the top international experts in immunology and immunotherapy to New…
-
Love Is On for $1 Million
Choose to love CRI in the second annual Revlon LOVE IS ON Million Dollar Challenge.
-
CRI Congratulates 2016 Lasker Award Winners
The Albert and Mary Lasker Foundation announced the 2016 recipients of the prestigious Lasker Awards, and CRI congratulates Charles…
-
Immunotherapy Patient Summit Agenda – Announced!
#CRISummit16 promises to be an educational and empowering day for cancer patients and their families.
-
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer
New hope now exists for patients with advanced head and neck cancer.
-
Cancer Research Institute Featured in New York Times Cover Story on Cancer Immunotherapy
The pioneering work of CRI and its funded scientists are profiled in this special feature from the…
-
LabAnswer and Its Employees Raise More Than $50,000 for CRI
In January of 2016, CRI formed a new corporate philanthropy partnership with LabAnswer, the largest independent laboratory…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.